 Positive results were obtained from the phase 3 GEM-3 study using VYJUVEK for the treatment of patients with dystrophic Epidermolysis Bullosa. STAR-D technology platform is highly efficient in using an engineered non-encoding HSV-1 viral vector to deliver a large gene or multiple genes to restore a functioning protein. 